Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05328102 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)
A Phase 2 study, sponsored by Xencor.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT05328102: Clinical Trial Phase 2 study, sponsored by Xencor.
NCT05328102 is a Phase 2 study that was terminated before completion, run by Xencor. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05328102, a Phase 2 study, was terminated before completion, sponsored by Xencor.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety and effectiveness of plamotamab when it is given with tafasitamab and lenalidomide in participants with relapsed or refractory DLBCL.
Primary Outcome
An adverse event (AE) was any untoward medical occurrence in a study participant. The AE did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug. AEs may have included the onset of new illness and the exacerbation of preexisting conditions. TEAEs were defined as events with onset dates on
Interventions
- DRUG Lenalidomide
- BIOLOGICAL Tafasitamab
- BIOLOGICAL Plamotamab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2022-04-15 |
| Est. Completion | 2023-02-21 |
| Phase | Phase 2 |
Why NCT05328102 stopped before completion
NCT05328102 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Lenalidomide is the first listed.
NCT05328102 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05328102 about?
NCT05328102 is a clinical study titled "Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)". The purpose of this study is to investigate the safety and effectiveness of plamotamab when it is given with tafasitamab and lenalidomide in participants with relapsed or refractory DLBCL.
What is the current status of trial NCT05328102?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2022-04-15. Estimated completion is 2023-02-21.
What interventions are being tested in trial NCT05328102?
The interventions under investigation include: Lenalidomide (DRUG), Tafasitamab (BIOLOGICAL), Plamotamab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05328102?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05328102's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI